Paediatric non‐Hodgkin lymphoma ‐ perspectives in translational biology

Shiramizu, Bruce; Mussolin, Lara; Woessmann, Wilhelm; Klapper, Wolfram

doi:10.1111/bjh.14009

Cited by 10 publications

(10 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past two decades there has been a steady increase in translational investigations in CAYA NHL. One of the more novel innovations in the last two decades is the precise measurement of minimal residual disease (MRD) and minimal disseminated disease (MDD) in patients during treatment and at diagnosis, respectively (Shiramizu et al, 2016). Established methods of leukaemia detection have included flow cytometry of aberrant phenotypes, polymerase chain reaction of fusion transcripts and/or antigen receptor genes (Shiramizu et al, 2016).…”

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

“…One of the more novel innovations in the last two decades is the precise measurement of minimal residual disease (MRD) and minimal disseminated disease (MDD) in patients during treatment and at diagnosis, respectively (Shiramizu et al, 2016). Established methods of leukaemia detection have included flow cytometry of aberrant phenotypes, polymerase chain reaction of fusion transcripts and/or antigen receptor genes (Shiramizu et al, 2016). Recently, MDD and MRD analysis has been demonstrated to be associated with risk assessment and prognostication in children and adolescents with NHL (Damm-Welk et al, 2007; Agsalda et al, 2009; Coustan-Smith et al, 2009; Mussolin et al, 2011; Shiramizu et al, 2016).…”

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

“…Established methods of leukaemia detection have included flow cytometry of aberrant phenotypes, polymerase chain reaction of fusion transcripts and/or antigen receptor genes (Shiramizu et al, 2016). Recently, MDD and MRD analysis has been demonstrated to be associated with risk assessment and prognostication in children and adolescents with NHL (Damm-Welk et al, 2007; Agsalda et al, 2009; Coustan-Smith et al, 2009; Mussolin et al, 2011; Shiramizu et al, 2016). Therefore, MDD and MRD evaluations have been incorporated into the International Paediatric NHL Staging Classification (IPNHLSC) and International Paediatric NHL Response Criteria (IPNHLRC) (Rosolen et al, 2015; Sandlund et al, 2015).…”

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

See 2 more Smart Citations

Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives

Cairo

Beishuizen

2019

Br J Haematol

View full text Add to dashboard Cite

The 6th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) was held in Rotterdam, Netherlands, 26-29 September, 2018. This summary manuscript is a perspective on the presentations from the plenary scientific sessions, including wellness and survivorship, B-cell NHL, AYA lymphoma, translational NHL biology, lymphoma immunology, bone marrow transplantation and cell therapy, T/Natural Killer cell lymphoma, anaplastic large cell lymphoma, lymphoblastic lymphoma, novel lymphoma therapeutics and Hodgkin lymphoma. The symposium was attended by over 260 registrants from 42 different countries and included young, middle and senior investigators. Finally, the Angelo Rosolen, MD, Memorial Lecture was delivered by Alfred Reiter, MD.

show abstract

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

Section: Caya Translational Nhl Biologymentioning

confidence: 99%

See 1 more Smart Citation

Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives

Cairo

Beishuizen

2019

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…ALCL is primarily a paediatric tumour, accounting for 15% of all paediatric Non-Hodgkin Lymphoma (NHL) with an annual incidence ranging from 1.2 per million in children under 15 years, to approximately 2 per million in young adults between 25 and 34 years [ 8 ], translating to approximately 80 new paediatric cases diagnosed in Europe each year [ 9 ]. Whilst the majority of paediatric cases are ALK-positive, about 50–60% of adult ALCL cases are ALK-negative.…”

Section: Clinical Features Of Paediatric Paediatric Anaplastic Larmentioning

confidence: 99%

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

Prokoph

Larose

Lim

et al. 2018

Cancers

View full text Add to dashboard Cite

Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65–90% of patients. Over the last two decades, major efforts have focused on improving the survival rate by intensification of combination chemotherapy regimens and employing stem cell transplantation for chemotherapy-resistant patients. More recently, several new and ‘renewed’ agents have offered the opportunity for a change in the paradigm for the management of both chemo-sensitive and chemo-resistant forms of ALCL. The development of ALK inhibitors following the identification of the EML4-ALK fusion gene in Non-Small Cell Lung Cancer (NSCLC) has opened new possibilities for ALK-positive ALCL. The uniform expression of CD30 on the cell surface of ALCL has given the opportunity for anti-CD30 antibody therapy. The re-evaluation of vinblastine, which has shown remarkable activity as a single agent even in the face of relapsed disease, has led to the consideration of a revised approach to frontline therapy. The advent of immune therapies such as checkpoint inhibition has provided another option for the treatment of ALCL. In fact, the number of potential new agents now presents a real challenge to the clinical community that must prioritise those thought to offer the most promise for the future. In this review, we will focus on the current status of paediatric ALCL therapy, explore how new and ‘renewed’ agents are re-shaping the therapeutic landscape for ALCL, and identify the strategies being employed in the next generation of clinical trials.

show abstract

“…Indeed, data from British Columbia suggests an incidence of diagnosed ALCL cases of under 4 per million children and young adults (Alessandri et al , ). In Europe, this represents fewer than 100 new cases per year (Shiramizu et al , ). In contrast EFS rates are lower, ranging from 59% to 76%, depending on the treatment protocol used (Minard‐Colin et al , ; Prokoph et al , ).…”

Section: The Current Prognosis: a Ceiling Has Been Hitmentioning

confidence: 99%

From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK+

et al. 2019

View full text Add to dashboard Cite

Anaplastic large cell lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma that mainly presents in paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting in hyperactivation of anaplastic lymphoma kinase (ALK) as the consequence of a chromosomal translocation. Rarer cases lack expression of ALK fusion proteins and are categorised as ALCL, ALKÀ. An adapted regimen of an historic chemotherapy backbone is still used to this day, yielding overall survival (OS) of over 90% but with event-free survival (EFS) at an unacceptable 70%, improving little over the past 30 years. It is clear that continued adaption of current therapies will probably not improve these statistics and, for progress to be made, integration of biology with the design and implementation of future clinical trials is required. Indeed, advances in our understanding of the biology of ALCL are outstripping our ability to clinically translate them; laboratory-based research has highlighted a plethora of potential therapeutic targets but, with high survival rates combined with a scarcity of funding and patients to implement paediatric trials of novel agents, progress is slow. However, advances must be made to reduce the side-effects of intensive chemotherapy regimens whilst maintaining, if not improving, OS and EFS.

show abstract

Paediatric non‐Hodgkin lymphoma ‐ perspectives in translational biology

Cited by 10 publications

References 61 publications

Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives

Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK+

Contact Info

Product

Resources

About